Product introduction
Menotas 75 Injection is used in the treatment of infertility in women. It is also helpful in the treatment of male hypogonadism (delayed puberty and low sperm count) and male infertility. It works by releasing the eggs from the ovary in women and by increasing the testosterone level in men.
Menotas 75 Injection is given as an injection under the supervision of a doctor. Your doctor will decide the right time to take the injection, so always follow your doctor’s advice. The dose and how often you take it depend on what you are taking it for. You might be prescribed certain other medicines as part of your treatment. You should take this medicine for as long as it is prescribed for you.
The most common side effects of this medicine include headache, injection site pain, injection site allergic reaction, abdominal swelling, or pain. If these bother you or appear serious, let your doctor know. There may be ways of reducing or preventing them. A male might notice acne, or sweating, and a deepening of the voice.
Before taking this medicine, tell your doctor if you have ever had heart disease, or had an ovarian cyst, or had thyroid gland disorder. Your doctor should also know about all other medicines you are taking, as many of these may make this medicine less effective or change the way it works. Tell your doctor if you are pregnant or breastfeeding. You should avoid alcohol or have to follow your doctor’s advice related to diet while taking this medicine.
Uses of Menotas Injection
- Treatment of Female infertility
- Treatment of Male hypogonadism
- Treatment of Male infertility
Benefits of Menotas Injection
In Treatment of Female infertility
Side effects of Menotas Injection
Common side effects of Menotas
- Headache
- Injection site pain
- Injection site allergic reaction
- Abdominal pain
- Abdominal cramp
- Nausea
How to use Menotas Injection
How Menotas Injection works
Safety advice

Alcohol

Pregnancy

Breast feeding

Driving

Kidney

Liver
What if you forget to take Menotas Injection?
Quick tips
- Menotas 75 Injection stimulates the production of eggs in women undergoing treatment for infertility.
- It may also be used to stimulate sperm formation in men.
- Your doctor may prescribe more than one medicine as part of your suggested pregnancy plan.
- Pregnancy following treatment with Menotas 75 Injection is more likely to result in a multiple pregnancy (twins or more) than if you had conceived naturally.
- The injection is administered under the skin. Follow the recommended dosage and monitoring schedules to minimise the possibility of ovarian hyperstimulation.
- Inform your doctor immediately if you have severe pelvic pain, nausea, vomiting, diarrhea, sudden weight gain, trouble breathing, or decreased or no urination during treatment, as these could be symptoms of ovarian hyperstimulation syndrome (OHSS).
- Do not use Menotas 75 Injection if you are already pregnant or breastfeeding.
FAQs
What is Menotas 75 Injection and what it is used for?
How and in what dose can it be used?
What if I miss a dose of Menotas 75 Injection?
What are the side effects of using Menotas 75 Injection?
References:-
- U.S. Food and Drug Administration (FDA) – Drug Label (Sutent/Sunitinib):
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021938s13s17s18lbl.pdf
- (The FDA label confirming the 25mg strength and explicitly outlining its role as a dose reduction step (2nd dose reduction for RCC/GIST, 1st dose reduction for pNET) to manage adverse events.)
- Philippines Food and Drug Administration (FDA) – Drug Registration (Example):
- https://verification.fda.gov.ph/ALL_DrugProductsview.php?showdetail=®istration_number=DRP-2095
- (Registration entry for Sutent 25mg Capsule (Sunitinib) in the Philippines FDA portal, confirming local approval and generic name.)
- Medscape – Professional Dosing and Interactions:
- https://reference.medscape.com/drug/sutent-sunitinib-342201
- (Detailed clinical dosing, emphasizing the use of 12.5mg increments/decrements, which leads to the 25mg maintenance/reduced dose, for safety and tolerability in RCC and GIST.)
- NIH – PubMed Central (PMC) – Pivotal Trial Efficacy (GIST):
- https://www.scilit.com/publications/027fab2ef65b4141ac9d597db0e92c13
- (FDA Approval Summary detailing Sunitinib’s superior Progression-Free Survival (PFS) in the pivotal Phase III GIST trial, a benefit the 25mg reduced dose seeks to maintain.)
- NIH – PubMed Central (PMC) – Real-World Pharmacokinetics/Dosing:
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9328649/
- (Study on the relationship between Sunitinib exposure and clinical outcomes, supporting flexible dosing (including 25mg) to optimize the balance between efficacy and toxicity.)


Reviews
There are no reviews yet.